ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Tamoxifen Trial may EB Funded In Part With CCOP Money

March 22, 1991

New Ultrasound Technique For Hard To Diagnose Cysts

June 29, 2001

Randomized Trials Discovered Roles For Newly Approved Nexavar and Sutent.

February 24, 2006

Fischinger Names Research VP at MUSC (Charleston); Meyskens Names Director Of New UC (Irvine Center)

October 28, 1988

NCI Says Review Group Will Read Blueprint, Evaluate NCI Research

January 16, 1998

In Brief: FDA Names DeLap Directory Of Oncology

June 7, 1996